<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004188</url>
  </required_header>
  <id_info>
    <org_study_id>A3973</org_study_id>
    <secondary_id>COG-A3973</secondary_id>
    <secondary_id>CCG-A3973</secondary_id>
    <secondary_id>POG-A3973</secondary_id>
    <secondary_id>CCG-39703</secondary_id>
    <secondary_id>FHCRC-1631.00</secondary_id>
    <secondary_id>CDR0000067429</secondary_id>
    <nct_id>NCT00004188</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma</brief_title>
  <official_title>A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

      PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation
      with treated peripheral stem cells following combination chemotherapy to see how well it
      works compared to peripheral stem cell transplantation with untreated peripheral stem cells
      following combination chemotherapy in treating patients with neuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the event-free survival in patients with newly diagnosed high risk neuroblastoma
           or ganglioneuroblastoma treated with myeloablative consolidation chemotherapy and
           autologous purged versus unpurged peripheral blood stem cells (PBSC).

        -  Compare the time to engraftment and CD34 content and tumor content by reverse
           transcriptase polymerase chain reaction (RT-PCR) of purged versus unpurged PBSC in
           patients treated with these regimens.

        -  Determine event-free survival of patients treated with dose intensive induction
           chemotherapy comprising cyclophosphamide, doxorubicin, and vincristine alternating with
           cisplatin and etoposide.

        -  Determine the toxicity of this dose-intensive induction chemotherapy regimen in these
           patients.

        -  Evaluate tumor resectability at second look or delayed surgery, response (complete
           response and very good partial response) at completion of induction therapy, tumor
           content of peripheral blood and bone marrow, and the comparison of historical data from
           CCG-3891 induction therapy in these patients.

      Secondary

        -  Compare the toxicity of this myeloablative consolidation regimen using purged vs
           unpurged PBSC in these patients.

        -  Determine if event-free survival is predictable by RT-PCR positivity of the stem cell,
           minimal residual disease in bone marrow and peripheral blood after transplantation by
           immunocytology, and extent of disease as measured by MIBG after transplantation in
           patients treated with these regimens.

        -  Evaluate the prognostic impact of tumor biology on event free survival in patients
           treated with these regimens.

        -  Determine the incidence of relapse in the primary site after radiotherapy and in
           irradiated versus unirradiated metastatic sites in these patients.

        -  Assess the toxicity and tolerability of maintenance therapy with topotecan and
           cyclophosphamide after intensive induction therapy in patients who decline or are unable
           to receive myeloablative therapy.

        -  Determine the health-related quality of life of patients treated with these regimens.

        -  Compare late effects of these regimens on the growth, endocrine, pulmonary, and cardiac
           function of these patients vs general population standards.

        -  Determine the incidence of second malignant neoplasms in patients treated with these
           regimens.

        -  Determine the variability of isotretinoin pharmacokinetics and relationship to
           pharmacogenomic parameters in these patients.

        -  Correlate the isotretinoin pharmacokinetics and pharmacogenomic parameters and/or
           genetic variations in isotretinoin metabolic enzymes with event-free survival or
           systemic toxicity in these patients.

      OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms for
      peripheral blood stem cell (PBSC) collection.

      All patients receive induction chemotherapy comprising cyclophosphamide IV over 6 hours on
      days 0 and 1, doxorubicin IV and vincristine IV continuously over 72 hours on days 0-2, and
      filgrastim (G-CSF) subcutaneously (SC) or IV beginning on day 3 and continuing until blood
      counts recover for courses 1, 2, 4, and 6. Treatment alternates with courses 3 and 5
      comprising etoposide IV over 2 hours on days 0-2, cisplatin IV over 1 hour on days 0-3, and
      G-CSF SC or IV beginning on day 4 and continuing until blood counts recover. Induction
      chemotherapy repeats every 3 weeks or when blood counts recover in the absence of disease
      progression or unacceptable toxicity.

      After course 2 or 3 of induction chemotherapy, patients undergo PBSC collection, either
      purged or unpurged, depending on randomization. Patients continue on daily G-CSF until cell
      collection is complete.

        -  Arm I: Patients undergo unpurged PBSC collection until the target cell count is reached.

        -  Arm II: Patients undergo purged PBSC collection until the target cell count is reached.

      Patients with immunocytology positive PBSC undergo purged autologous bone marrow collection
      or repeat purged or unpurged PBSC collection depending on individual patient characteristics.

      All patients undergo delayed surgical resection of the residual tumor after course 5 of
      induction chemotherapy.

      After induction therapy, patients achieving complete response, very good partial response, or
      partial response receive consolidation therapy comprising melphalan IV on days -7 to -5
      followed by carboplatin IV and etoposide IV continuously over days -7 to -4. Patients receive
      purged or unpurged PBSC infusion or purged autologous bone marrow transplantation on day 0
      followed by G-CSF SC or IV beginning 4 hours after completion of transplantation and
      continuing until blood counts recover. Beginning on day 66, patients receive oral
      isotretinoin twice daily for 14 days. Isotretinoin therapy repeats every 4 weeks for 6
      courses.

      After completion of consolidation (at least 28 days from stem cell infusion), all patients
      receive local radiotherapy daily over 7 days.

      Patients not undergoing transplantation or who are ineligible for consolidation therapy
      receive maintenance therapy comprising cyclophosphamide IV over 30 minutes followed by
      topotecan IV over 30 minutes on days 0-4. Patients receive G-CSF SC or IV beginning on day 5
      and continuing until blood counts recover. Maintenance therapy repeats every 3 weeks for 3
      courses. After completion of maintenance therapy, patients receive radiotherapy as outlined
      above. Patients then receive oral isotretinoin twice daily for 14 days. Isotretinoin therapy
      repeats every 4 weeks for 6 courses.

      Quality of life is assessed at 1* and 5 years.

      Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then
      annually thereafter or until disease progression.

      NOTE: * Patients under 5 years of age at 1 year are not assessed until 5 years.

      PROJECTED ACCRUAL: A total of 486 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival rate</measure>
    <time_frame>Time from study registration until the time of the first occurrence of either relapse, progression, secondary malignancy, or death, or until the time of last contact with the patient if none of these events occurs, assessed up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of occurrence of toxic (non disease-related) deaths where a toxic death will be &quot;counted&quot; if it occurs prior to the initiation of the immunotherapy</measure>
    <time_frame>Up to day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Engraftment is defined as three consecutive measurements of ANC &gt; 500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34 content</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor content as measured by reverse transcriptase polymerase chain reaction</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction-3 wks (cyclophosphamide day 0&amp;1, doxorubicin hydrochloride &amp; vincristine sulfate day 0-2 &amp; filgrastim(G-CSF) day 3 crs 1,2,4 &amp; 6.) Crs 3 &amp; 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin &amp; etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction-3 wks (cyclophosphamide day 0&amp;1, doxorubicin hydrochloride &amp; vincristine sulfate day 0-2 &amp; filgrastim(G-CSF) day 3 crs 1,2,4 &amp; 6.) Crs 3 &amp; 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin &amp; etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <other_name>GRANULOCYTE COLONY-STIMULATING FACTOR</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>NSC 614629</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>NSC #241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>Cis-diamminedichloroplatinum II</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>NSC #11987</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>NSC #026271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>NSC #123127</other_name>
    <other_name>IND #7038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>VePesid</other_name>
    <other_name>Etopophos</other_name>
    <other_name>NSC #141540</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>13-cis-retinoic acid</other_name>
    <other_name>RO-43</other_name>
    <other_name>780</other_name>
    <other_name>Accutane</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>Claravis</other_name>
    <other_name>NSC 329481</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>phenylalanine mustard</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>NSC 008806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>SKF-104864</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>NSC #609699</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #067574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days</description>
    <arm_group_label>Arm I (unpurged PBSC collection)</arm_group_label>
    <arm_group_label>Arm II (unpurged PBSC collection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed neuroblastoma OR ganglioneuroblastoma, and/or
             evidence of clumps of tumor cells in bone marrow with elevated urinary catecholamine
             metabolites, meeting 1 of the following criteria:

               -  Age greater than 18 months with stage IV disease, regardless of biologic factors

               -  Age 12-18 months with stage IV disease meeting one of the following criteria:

                    -  Any unfavorable biologic feature (e.g., MYCN amplification, unfavorable
                       pathology, and/or DNA index = 1)

                    -  Any biologic feature that is indeterminate, unsatisfactory, or unknown

          -  At least 1 year old with the following:

               -  Stage IIa/IIb with MYCN amplification (&gt; 10) AND unfavorable pathology

               -  Stage III with MYCN amplification (&gt; 10) OR unfavorable pathology

               -  Stage I, II, or IVS with disease progression to stage IV without interval
                  chemotherapy

                    -  No more than 3 weeks since progression

                    -  Must have been enrolled on protocol CCG-B973, COG-ANBL00B1, or POG-9047

          -  Less than 1 year old with the following:

               -  Stage III, IV, or IVS disease with MYCN amplification (&gt; 10)

          -  Registration on protocol COG-ANBL00B1 required within 14 days of diagnosis

        PATIENT CHARACTERISTICS:

        Age:

          -  See Disease Characteristics

          -  30 and under at time of diagnosis

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Inadequate hematopoiesis secondary to bone marrow involvement with &gt; 10% tumor
             infiltration allowed

        Hepatic:

          -  Bilirubin ≤ 1.5 mg/dL

          -  ALT ≤ 300 units/L

        Renal:

          -  Creatinine ≤ 1.5 mg/dL

          -  Creatinine clearance or glomerular filtration rate ≥ 60 mL/min

        Cardiovascular:

          -  ECG normal

          -  Ejection fraction ≥ 55% by echocardiogram or MUGA OR

          -  Fractional shortening ≥ 28% by echocardiogram

        Other:

          -  Able to tolerate peripheral blood stem cell collection

          -  HIV negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for at least 1 month prior to,
             during, and for 1 month after study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  No more than 1 prior course of chemotherapy on the Intergroup low/intermediate risk
             neuroblastoma study (P9641, A3961)

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior localized emergency radiotherapy to sites of life-threatening or
             function-threatening disease allowed

        Surgery:

          -  Not specified

        Other

          -  No other prior systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan G. Kreissman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242-2814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonathan Jaques Children's Cancer Center at Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-1865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93638-8762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Oakland</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Health Center - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218-1088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06360-2875</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Cancer Care of Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center Cancer Center</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Cancer Institute at St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Cancer Center at St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Indianapolis Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markey Cancer Center at University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare of Maine at Eastern Maine Medial Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Cancer Care - Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503-2560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-5341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breslin Cancer Center at Ingham Regional Medical Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview University Medical Center - University Campus</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-2306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research and Treatment Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals - Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-5217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404-1815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Ohio Cancer Institute</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health South Carolina Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sioux Valley Hospital and University of South Dakota Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center School of Medicine</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-9958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Cancer Center of Western Virginia</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220-2555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edwards Comprehensive Cancer Center at Cabell Huntington Hospital</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center at West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's &amp; Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Children's Health and Rehabilitation Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <reference>
    <citation>Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012;2012:250834. doi: 10.1155/2012/250834. Epub 2012 Sep 25.</citation>
    <PMID>23050139</PMID>
  </reference>
  <reference>
    <citation>Cantos MF, Gerstle JT, Irwin MS, Pappo A, Farley S, Cheang T, Kim PC. Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma. J Pediatr Surg. 2006 May;41(5):960-5.</citation>
    <PMID>16677893</PMID>
  </reference>
  <reference>
    <citation>Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006 Jul 15;107(2):417-22.</citation>
    <PMID>16779793</PMID>
  </reference>
  <results_reference>
    <citation>Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20;32(6):527-34. doi: 10.1200/JCO.2013.51.2038. Epub 2014 Jan 13.</citation>
    <PMID>24419114</PMID>
  </results_reference>
  <results_reference>
    <citation>Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 1;56(7):1041-5. doi: 10.1002/pbc.22991. Epub 2011 Feb 15.</citation>
    <PMID>21328522</PMID>
  </results_reference>
  <results_reference>
    <citation>Yanik GA, Parisi MT, Naranjo A, et al.: MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. [Abstract] J Clin Oncol 28 (Suppl 15): A-9516, 2010.</citation>
  </results_reference>
  <results_reference>
    <citation>Kreissman SG, Villablanca JG, Diller L, et al.: Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. [Abstract] J Clin Oncol 25 (Suppl 18): A-9505, 527s, 2007.</citation>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

